# Aerpio Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/aerpio-therapeutics

- Industry: Pharmaceuticals
- Headquarters: Cincinnati, US
- Website: www.aerpio.com
- Total disclosed funding: $49M
- Latest round: Series A (Apr 22, 2014)
- Investors on record: 10

## About

Aerpio Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for ocular diseases, particularly those related to vascular dysfunction. Their approach is centered on addressing unmet medical needs in this area.Founded in 2011, Aerpio Therapeutics, Inc. is based in Cincinnati, US. The company specializes in the development of therapeutics targeting ocular conditions. In April 2014, the company completed its SERIES A funding round, raising USD 22.00 mn, led by OrbiMed Advisors with participation from multiple investors including Athenian Venture Partners and Novartis Venture Fund. The total amount raised by the company stands at USD 22.00 mn, with a current valuation of USD 72.11 mn. Joseph Gardner is the founder of Aerpio Therapeutics, and he has a history of entrepreneurial ventures in the biopharmaceutical sector.Aerpio Therapeutics, Inc. engages in the development of premium pharmaceutical therapies aimed at treating ocular diseases, primarily focusing on conditions linked to vascular dysfunction. The company's unique offerings include innovative products that address significant medical needs in the ophthalmic field, contributing to improved patient outcomes.Revenue for Aerpio Therapeutics, Inc. is primarily generated through the commercialization of its pharmaceutical products. The firm employs various pricing strategies, allowing for flexible access to its therapies, but specific financial details regarding revenue figures were not disclosed in the provided data.Aerpio Therapeutics, Inc. is focused on expanding its product line with upcoming therapies aimed at treating additional ocular diseases, leveraging recent funding from its SERIES A round completed in April 2014. The company plans to utilize the USD 22.00 mn raised to further develop its pipeline and enhance its market presence, targeting both North America and Europe for expansion. Strategic initiatives include increasing collaborations with research institutions and pharmaceutical partners to accelerate product development and access new markets.

## Funding rounds

- Series A, Apr 22, 2014, $22M — Athenian Venture Partners, OrbiMed Advisors, Venture Investors, Novartis Venture Fund, Triathlon Medical Partners, Kearny Venture Partners, CincyTech, Alerce Investment Management
- Series A, Nov 15, 2013, $9M — Athenian Venture Partners, Venture Investors, Novartis Venture Fund, Triathlon Medical Partners, Kearny Venture Partners, Alerce Investment Management
- Series A, Sep 12, 2013, $8M — Venture Investors, Novartis Venture Fund, Kearny Venture Partners
- Series A, Aug 28, 2012, $10M — Athenian Venture Partners, Venture Investors, Novartis Venture Fund, Triathlon Medical Partners, GeneChem, Kearny Venture Partners, AgeChem

## Investors

- Athenian Venture Partners (https://capitalatlas.ai/funds/athenian-venture-partners) — Series A
- Venture Investors — Series A
- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Series A
- Triathlon Medical Partners (https://capitalatlas.ai/funds/triathlon-medical-partners) — Series A
- GeneChem (https://capitalatlas.ai/funds/genechem) — Series A
- Kearny Venture Partners (https://capitalatlas.ai/funds/kearny-venture-partners) — Series A
- AgeChem (https://capitalatlas.ai/funds/agechem) — Series A
- Alerce Investment Management — Series A
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series A
- CincyTech (https://capitalatlas.ai/funds/cincytech) — Series A